Cel-Sci Corporation (CVM) financial statements (2023 and earlier)

Company profile

Business Address 8229 BOONE BLVD .
VIENNA, VA 22182
State of Incorp. CO
Fiscal Year End September 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments37,11042,21215,5098,44510,3102,369
Cash and cash equivalents37,11036,06015,5098,44510,3102,369
Short-term investments 6,151    
Receivables55555563119218
Inventory, net of allowances, customer advances and progress billings 2,007820782645673
Inventory 2,007820782645673
Prepaid expense7249981,313525365826
Deposits current assets     150
Other undisclosed current assets3,979     
Total current assets:41,86745,27217,6979,81511,4394,237
Noncurrent Assets
Finance lease, right-of-use asset12,25312,69213,812 
Operating lease, right-of-use asset2,0142,0561,199 
Property, plant and equipment13,29013,6645,84415,82616,21916,793
Intangible assets, net (including goodwill) 276313312258223
Intangible assets, net (excluding goodwill) 276313312258223
Other undisclosed noncurrent assets2481,911(19,468)1,6711,6711,671
Total noncurrent assets:27,80430,5981,70017,80818,14818,687
Other undisclosed assets  21,139   
TOTAL ASSETS:69,67275,87040,53627,62329,58622,924
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,0932,5352,5341,6215,9499,133
Accounts payable1,1931,6762,0231,5865,7448,196
Accrued liabilities90085951134205937
Debt     994
Derivative instruments and hedges, liabilities24372146742,49911
Due to related parties475266448709765694
Other liabilities   151412
Other undisclosed current liabilities7646991,070   
Total current liabilities:3,3333,9374,2663,0209,22710,845
Noncurrent Liabilities
Long-term debt and lease obligation14,86215,27412,867   
Finance lease, liability12,88013,25211,753 
Operating lease, liability1,9812,0211,114 
Liabilities, other than long-term debt1251253,6775,8366,8522,080
Other liabilities125125125233337
Derivative instruments and hedges, liabilities  3,5525,8146,8182,042
Other undisclosed noncurrent liabilities   13,63313,50713,337
Total noncurrent liabilities:14,98715,39916,54419,47020,35915,417
Total liabilities:18,32019,33620,81022,48929,58626,261
Stockholders' equity
Stockholders' equity attributable to parent51,35156,53419,7275,1341(3,337)
Common stock433432387352280119
Additional paid in capital477,898474,299401,175358,508331,312296,298
Accumulated deficit(426,979)(418,196)(381,835)(353,726)(331,592)(299,754)
Total stockholders' equity:51,35156,53419,7275,1341(3,337)
TOTAL LIABILITIES AND EQUITY:69,67275,87040,53627,62329,58622,924

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
Revenues  559737169
Other income  559737169
Gross profit:  559737169
Operating expenses(36,307)(36,194)(29,544)(20,658)(17,249)(21,407)
Other undisclosed operating income365  390406 
Operating loss:(36,307)(36,194)(28,985)(20,195)(16,772)(21,338)
Nonoperating income1,8891,677926546  
Investment income, nonoperating1,6481,685888546  
Interest and debt expense  (1,200) (291) 
Loss from continuing operations before equity method investments, income taxes:(34,418)(34,517)(29,259)(19,650)(17,063)(21,338)
Other undisclosed loss from continuing operations before income taxes(3,302) (997)   
Loss before gain (loss) on sale of properties:(37,720)(34,517)(30,255)(19,650)(17,063)(21,338)
Other undisclosed net loss(272)     
Net loss:(37,992)(34,517)(30,255)(19,650)(17,063)(21,338)
Other undisclosed net income (loss) attributable to parent785(1,844) (2,485)(14,774)6,975
Net loss attributable to parent:(37,207)(36,361)(30,255)(22,135)(31,837)(14,363)
Other undisclosed net loss available to common stockholders, basic(265)(351)(22) (14)(64)
Net loss available to common stockholders, basic:(37,472)(36,712)(30,277)(22,135)(31,852)(14,427)
Other undisclosed net loss available to common stockholders, diluted(1,108)(1,086)   (677)
Net loss available to common stockholders, diluted:(38,580)(37,798)(30,277)(22,135)(31,852)(15,104)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
9/30/2021
9/30/2020
9/30/2019
9/30/2018
9/30/2017
Net loss:(37,992)(34,517)(30,255)(19,650)(17,063)(21,338)
Comprehensive loss, net of tax, attributable to parent:(37,992)(34,517)(30,255)(19,650)(17,063)(21,338)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: